# StemMedical A/S

Gyngemose Parkvej 50, DK-2860 Søborg

# Annual Report for 1 January - 31 December 2021

CVR No 35 85 28 08

The Annual Report was presented and adopted at the Annual General Meeting of the Company on 2 /5 2022

Peter Bo Selvig Chairman of the General Meeting



# **Contents**

	Page
Management's Statement and Auditor's Report	
Management's Statement	1
The Independent Practitioner's Report	2
Company Information	
Company Information	4
Management's Review	5
Financial Statements	
Income Statement 1 January - 31 December	6
Balance Sheet 31 December	7
Statement of Changes in Equity	9
Notes to the Financial Statements	10



# **Management's Statement**

The Executive Board and Board of Directors have today considered and adopted the Annual Report of StemMedical A/S for the financial year 1 January - 31 December 2021.

The Annual Report is prepared in accordance with the Danish Financial Statements Act.

In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2021 of the Company and of the results of the Company operations for 2021.

In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Søborg, 2 May 2022

#### **Executive Board**

Stig-Frederik Trojahn Kølle CEO

Peter Bo Selvig Executive Officer

#### **Board of Directors**

Stig Løkke Pedersen Christian Nissen Riisberg Nis Isak Alstrup Chairman Deputy Chairman

Christina Molt Wengel Stig-Frederik Trojahn Kølle Anders Christian Wolf Kølle

Erik Aznauryan



# The Independent Practitioner's Report

To the Shareholders of StemMedical A/S

#### Conclusion

We have performed an extended review of the Financial Statements of StemMedical A/S for the financial year 1 January - 31 December 2021, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The Financial Statements are prepared in accordance with the Danish Financial Statements Act.

Based on the work performed, in our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2021 and of the results of the Company operations for the financial year 1 January - 31 December 2021 in accordance with the Danish Financial Statements Act.

#### **Basis for conclusion**

We conducted our extended review in accordance with the Danish Business Authority's Assurance Standard for Small Enterprises and FSR – Danish Auditors' standard on extended review of financial statements prepared in accordance with the Danish Financial Statements Act. Our responsibilities under those standards and requirements are further described in the "Practitioner's responsibilities for the extended review of the financial statements" section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.

## Management's responsibility for the Financial Statements

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the Financial Statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

#### Practitioner's responsibilities for the extended review of the Financial Statements

Our responsibility is to express a conclusion on the Financial Statements. This requires that we plan and perform procedures to obtain limited assurance in respect of our conclusion on the Financial Statements and, moreover, that we perform supplementary procedures specifically required to obtain additional assurance in respect of our conclusion.



# The Independent Practitioner's Report

An extended review consists of making inquiries, primarily of Management and others within the enterprise, as appropriate, and applying analytical procedures and the supplementary procedures specifically required as well as assessing the evidence obtained.

An extended review is less in scope than an audit and, consequently, we do not express an audit opinion on the Financial Statements.

## Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the Financial Statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our extended review of the Financial Statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the Financial Statements or our knowledge obtained during the extended review, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financials Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

Hellerup, 2 May 2022 **PricewaterhouseCoopers** Statsautoriseret Revisionspartnerselskab *CVR No 33 77 12 31* 

Thomas Baunkjær Andersen statsautoriseret revisor mne35483



# **Company Information**

The Company StemMedical A/S

Gyngemose Parkvej 50 DK-2860 Søborg

CVR No: 35 85 28 08

Financial period: 1 January - 31 December

Incorporated: 2 May 2014 Financial year: 8th financial year Municipality of reg. office: Gladsaxe

**Board of Directors** Stig Løkke Pedersen, Chairman

Christian Nissen Riisberg

Nis Isak Alstrup

Christina Molt Wengel Stig-Frederik Trojahn Kølle Anders Christian Wolf Kølle

Erik Aznauryan

**Executive Board** Stig-Frederik Trojahn Kølle

Peter Bo Selvig

**Auditors** PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab

Strandvejen 44 DK-2900 Hellerup



# **Management's Review**

# **Key activities**

The company's objective is to operate business related to plastic surgery.

#### Development in the year

The income statement of the Company for 2021 shows a loss of DKK 13,221,367, and at 31 December 2021 the balance sheet of the Company shows equity of DKK 16,385,120.

## **Capital resources**

After the balance sheet date, the company has carried out a capital increase of nominal DKK 28,446, which has provided the company with DKK 14.9 million in liquidity.

Based on the completed capital increase, it is management's assessment the company's capital resources are sufficient to ensure continued operations in 2022.

# **Subsequent events**

No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date, other than what is described in the capital resources section.



# **Income Statement 1 January - 31 December**

	Note	2021	2020
		DKK	DKK
O		4.074.045	0.700.050
Gross profit/loss		-4,371,015	-3,792,953
Staff expenses	1	-8,822,452	-3,719,213
Depreciation, amortisation and impairment of intangible assets and			
property, plant and equipment	2	-1,265,172	-1,108,127
Profit/loss before financial income and expenses		-14,458,639	-8,620,293
Financial expenses		-88,074	-92,496
Profit/loss before tax		-14,546,713	-8,712,789
Tax on profit/loss for the year	3	1,325,346	976,223
Net profit/loss for the year		-13,221,367	-7,736,566
Distribution of profit			
Distribution of profit			
Proposed distribution of profit			
Retained earnings		-13,221,367	-7,736,566
		-13,221,367	-7,736,566



# **Balance Sheet 31 December**

# Assets

	Note	2021	2020
		DKK	DKK
Acquired patents		1,219,654	1,212,400
Goodwill		0	0
Development projects in progress		0	0
Intangible assets	4	1,219,654	1,212,400
Other fixtures and fittings, tools and equipment		2,171,606	1,960,787
Leasehold improvements	_	403,066	44,099
Property, plant and equipment	5	2,574,672	2,004,886
Deposits		180,936	95,342
Fixed asset investments	· -	180,936	95,342
Fixed assets		3,975,262	3,312,628
Inventories		941,039	269,723
Other receivables		867,234	528,221
Corporation tax	_	1,325,346	976,223
Receivables		2,192,580	1,504,444
Cash at bank and in hand		11,108,053	26,061,865
Currents assets		14,241,672	27,836,032
Assets		18,216,934	31,148,660



# **Balance Sheet 31 December**

# Liabilities and equity

	Note	2021	2020
		DKK	DKK
Share capital	6	595,290	595,290
Retained earnings		15,789,830	29,011,197
Equity	-	16,385,120	29,606,487
Lease obligations		0	167,571
Trade payables		968,435	577,597
Other payables		863,379	734,862
Deferred income	_	0	62,143
Short-term debt	-	1,831,814	1,542,173
Debt	-	1,831,814	1,542,173
Liabilities and equity	-	18,216,934	31,148,660
Contingent assets, liabilities and other financial obligations	7		
Accounting Policies	8		



# **Statement of Changes in Equity**

		Retained		
	Share capital	earnings	Total	
	DKK	DKK	DKK	
Equity at 1 January	595,290	29,011,197	29,606,487	
Net profit/loss for the year	0	-13,221,367	-13,221,367	
Equity at 31 December	595,290	15,789,830	16,385,120	



		2021	2020
	C. CC	DKK	DKK
1	Staff expenses		
	Wages and salaries	8,020,137	3,327,903
	Pensions	747,559	364,014
	Other staff expenses	54,756	27,296
		8,822,452	3,719,213
	Average number of employees	9	5
2	Depreciation, amortisation and impairment of intangible assets and property, plant and equipment		
	Amortisation of intangible assets	174,419	152,362
	Depreciation of property, plant and equipment	1,152,896	1,204,336
	Gain and loss on disposal	-62,143	-248,571
		1,265,172	1,108,127
3	Tax on profit/loss for the year		
	Current tax for the year	-1,325,346	-976,223
		-1,325,346	-976,223



# 4 Intangible assets

-		Acquired pa-		Development projects in
		tents	Goodwill	progress
		DKK	DKK	DKK
	Cost at 1 January	1,685,928	66,333	600,000
	Additions for the year	181,673	0	0
	Cost at 31 December	1,867,601	66,333	600,000
	Impairment losses and amortisation at 1 January	473,528	66,333	600,000
	Amortisation for the year	174,419	0	0
	Impairment losses and amortisation at 31 December	647,947	66,333	600,000
	Carrying amount at 31 December	1,219,654	0	0
	Amortised over	10 years	5 years	
5	Property, plant and equipment			
			Other fixtures	
			and fittings,	
			tools and	Leasehold
			equipment DKK	improvements DKK
	Cost at 1 January		6,004,415	520,240
	Additions for the year		1,313,529	409,153
	Cost at 31 December		7,317,944	929,393
	Impairment losses and depreciation at 1 January		4,043,628	476,141
	Depreciation for the year		1,102,710	50,186
	Impairment losses and depreciation at 31 December		5,146,338	526,327
	Carrying amount at 31 December		2,171,606	403,066
	Depreciated over		5 years	5 years



# 6 Equity

The share capital consists of 595,290 shares of a nominal value of DKK 1. No shares carry any special rights.

The share capital has developed as follows:

	2021	2020	2019	2018	2017
Share capital at 1 January	DKK 595,290	DKK 525,965	DKK 514,653	DKK 222,547	DKK 220,447
Capital increase	0	69,325	11,312	292,106	2,100
Share capital at 31					
December	595,290	595,290	525,965	514,653	222,547

2021	2020
DKK	DKK

## 7 Contingent assets, liabilities and other financial obligations

## **Contingent assets**

The Company has a basis for calculating of deferred tax amounting TDKK 16.723. The nominal value of this amounts to 22% in total TDKK 3.679. Management has chosen not to recognise the deferred tax asset due to uncertainty about the Company's ability to use the deferred tax asset, as it can be attributed primarily to tax losses carried forward.

#### Rental and lease obligations

Lease obligations under operating leases. Total future lease payments:

Within 1 year	219,741	127,428
	219,741	127,428



### 8 Accounting Policies

The Annual Report of StemMedical A/S for 2021 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B as well as selected rules applying to reporting class C.

The accounting policies applied remain unchanged from last year.

The Financial Statements for 2021 are presented in DKK.

## **Recognition and measurement**

Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

#### Leases

Leases in terms of which the Company assumes substantially all the risks and rewards of ownership (finance leases) are recognised in the balance sheet at the lower of the fair value of the leased asset and the net present value of the lease payments computed by applying the interest rate implicit in the lease or an alternative borrowing rate as the discount rate. Assets acquired under finance leases are depreciated and written down for impairment under the same policy as determined for the other fixed assets of the Company.

The remaining lease obligation is capitalised and recognised in the balance sheet under debt, and the interest element on the lease payments is charged over the lease term to the income statement.

All other leases are considered operating leases. Payments made under operating leases are recognised in the income statement on a straight-line basis over the lease term.



#### 8 Accounting Policies (continued)

#### **Translation policies**

Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Exchange differences arising due to differences between the transaction date rates and the rates at the dates of payment are recognised in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognised directly in equity.

Receivables, payables and other monetary items in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date. Any differences between the exchange rates at the balance sheet date and the rates at the time when the receivable or the debt arose are recognised in financial income and expenses in the income statement.

Fixed assets acquired in foreign currencies are measured at the transaction date rates.

## **Income Statement**

#### Revenue

Revenue from the sale of goods is recognised when the risks and rewards relating to the goods sold have been transferred to the purchaser, the revenue can be measured reliably and it is probable that the economic benefits relating to the sale will flow to the Company.

Revenue is measured at the consideration received and is recognised exclusive of VAT and net of discounts relating to sales.

#### **Expenses for raw materials and consumables**

Expenses for raw materials and consumables comprise the raw materials and consumables consumed to achieve revenue for the year.

#### Other external expenses

Other external expenses comprise expenses for premises, sales and distribution as well as office expenses, etc.

#### Gross profit/loss

With reference to section 32 of the Danish Financial Statements Act, gross profit/loss is calculated as a summary of revenue, other operating income, expenses for raw materials and consumables and other external expenses.



### 8 Accounting Policies (continued)

## Staff expenses

Staff expenses comprise wages and salaries as well as payroll expenses.

#### Amortisation, depreciation and impairment losses

Amortisation, depreciation and impairment losses comprise amortisation, depreciation and impairment of intangible assets and property, plant and equipment.

### Other operating income and expenses

Other operating income and other operating expenses comprise items of a secondary nature to the main activities of the Company.

## Financial income and expenses

Financial income and expenses are recognised in the income statement at the amounts relating to the financial year.

## Tax on profit/loss for the year

Tax for the year consists of current tax for the year and changes in deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity transactions is recognised directly in equity.

# **Balance Sheet**

#### **Intangible assets**

Goodwill acquired is measured at cost less accumulated amortisation. Goodwill is amortised on a straight-line basis over its useful life, which is assessed at 5 years.

Patents and licences are measured at the lower of cost less accumulated amortisation and recoverable amount. Patents are amortised over the remaining patent period, and licences are amortised over the licence period; however not exceeding 10 years.

Development costs and costs relating to rights developed by the Company are recognised in the income statement as costs in the year of acquisition.



### 8 Accounting Policies (continued)

## Property, plant and equipment

Property, plant and equipment are measured at cost less accumulated depreciation and less any accumulated impairment losses.

Cost comprises the cost of acquisition and expenses directly related to the acquisition up until the time when the asset is ready for use.

Interest expenses on loans raised directly for financing the construction of property, plant and equipment are recognised in cost over the period of construction.

Depreciation based on cost reduced by any residual value is calculated on a straight-line basis over the expected useful lives of the assets, which are:

Other fixtures and fittings, tools and equipment 5 years Leasehold improvements 5 years

Depreciation period and residual value are reassessed annually.

#### Impairment of fixed assets

The carrying amounts of intangible assets and property, plant and equipment are reviewed on an annual basis to determine whether there is any indication of impairment other than that expressed by amortisation and depreciation.

If so, the asset is written down to its lower recoverable amount.

#### **Fixed asset investments**

Fixed asset investments consist of deposits.

### **Inventories**

Inventories are measured at the lower of cost under the FIFO method and net realisable value.

The net realisable value of inventories is calculated at the amount expected to be generated by sale of the inventories in the process of normal operations with deduction of selling expenses. The net realisable value is determined allowing for marketability, obsolescence and development in expected selling price.

The cost of raw materials and consumables equals landed cost.



#### 8 Accounting Policies (continued)

#### **Receivables**

Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts.

#### Deferred tax assets and liabilities

Deferred income tax is measured using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes on the basis of the intended use of the asset and settlement of the liability, respectively.

Deferred tax assets are measured at the value at which the asset is expected to be realised, either by elimination in tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity.

Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation at the balance sheet date when the deferred tax is expected to crystallise as current tax. Any changes in deferred tax due to changes to tax rates are recognised in the income statement or in equity if the deferred tax relates to items recognised in equity.

#### Current tax receivables and liabilities

Current tax liabilities and receivables are recognised in the balance sheet as the expected taxable income for the year adjusted for tax on taxable incomes for prior years and tax paid on account. Extra payments and repayment under the on-account taxation scheme are recognised in the income statement in financial income and expenses.

#### **Financial debts**

Debts are measured at amortised cost, substantially corresponding to nominal value.

#### **Deferred income**

Prepayments recognized as deferred income is made up by a profit on a sale of sale and lease back agreement and deferred government grants.

